Lu sur https://www.ncbi.nlm.nih.gov/pubmed/28440223
Traduction disponible directement en cliquant en bas à droite de ce message sur notre forum
Structural insights into the molecular mechanisms of myasthenia gravis and their therapeutic implications.
Noridomi K1, Watanabe G2, Hansen MN3, Han GW4, Chen L1,2,3.
Elife. 2017 Apr 25;6. pii: e23043. doi: 10.7554/eLife.23043.
Abstract
The nicotinic acetylcholine receptor (nAChR) is a major target of autoantibodies in myasthenia gravis (MG), an autoimmune disease that causes neuromuscular transmission dysfunction. Despite decades of research, the molecular mechanisms underlying MG have not been fully elucidated.
Here, we present the crystal structure of the nAChR α1 subunit bound by the Fab fragment of mAb35, a reference monoclonal antibody that causes experimental MG and competes with ~65% of antibodies from MG patients.
Our structures reveal for the first time the detailed molecular interactions between MG antibodies and a core region on nAChR α1.
These structures suggest a major nAChR-binding mechanism shared by a large number of MG antibodies and the possibility to treat MG by blocking this binding mechanism. Structure-based modeling also provides insights into antibody-mediated nAChR cross-linking known to cause receptor degradation.
Our studies establish a structural basis for further mechanistic studies and therapeutic development of MG.
Voici le lien direct vers l'article complet https://elifesciences.org/content/6/e23043#api_box
Attention, le système de traduction automatique du site ne fonctionnera pas pour la lecture de l'article complet.
Vous pouvez utiliser le service "Google traduction" pour cela
Voici le lien direct vers ce service pour cet article
https://translate.google.fr/translate?s ... t=&act=url
